Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Polyrizon Ltd. ( (PLRZ) ) just unveiled an announcement.
Polyrizon Ltd., a pre-clinical-stage biotech specializing in intranasal hydrogel-based nasal sprays to block viruses and allergens, is advancing a proprietary Capture and Contain platform and an early-stage Trap and Target drug-delivery technology. The Israel-based company targets preventive and therapeutic respiratory applications by creating a “biological mask” within the nasal cavity.
On March 10, 2026, Polyrizon announced it had successfully produced a Good Manufacturing Practice batch of clinical trial material for its lead intranasal product candidate. The batch, manufactured by Eurofins CDMO AmatsiAquitaine S.A.S after two consistent development runs, marks a key step toward a planned U.S. clinical study later in 2026 and strengthens the company’s operational readiness and clinical pathway for its respiratory protection technology.
More about Polyrizon Ltd.
Polyrizon Ltd. is a pre-clinical-stage biotechnology company developing innovative intranasal medical device hydrogels delivered as nasal sprays. Its proprietary Capture and Contain platform aims to form a thin hydrogel barrier in the nasal cavity to protect against airborne viruses and allergens, while an earlier-stage Trap and Target technology focuses on intranasal delivery of active pharmaceutical ingredients.
Average Trading Volume: 111,823
Technical Sentiment Signal: Sell
Current Market Cap: $20.69M
Learn more about PLRZ stock on TipRanks’ Stock Analysis page.